CN103385902B - Traditional Chinese medicine Herba Cirsii effective part extract, and preparation method, medicinal composition and use thereof - Google Patents
Traditional Chinese medicine Herba Cirsii effective part extract, and preparation method, medicinal composition and use thereof Download PDFInfo
- Publication number
- CN103385902B CN103385902B CN201210145120.1A CN201210145120A CN103385902B CN 103385902 B CN103385902 B CN 103385902B CN 201210145120 A CN201210145120 A CN 201210145120A CN 103385902 B CN103385902 B CN 103385902B
- Authority
- CN
- China
- Prior art keywords
- herba cirsii
- extract
- purposes according
- aqueous
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 239000000203 mixture Substances 0.000 title abstract description 7
- 238000000605 extraction Methods 0.000 title description 4
- -1 flavonoid compounds Chemical class 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 229930003935 flavonoid Natural products 0.000 claims abstract description 3
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 19
- 238000001556 precipitation Methods 0.000 claims description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 14
- 208000025865 Ulcer Diseases 0.000 claims description 13
- 229930003944 flavone Natural products 0.000 claims description 13
- 235000011949 flavones Nutrition 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 10
- 230000000274 adsorptive effect Effects 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 6
- 230000036269 ulceration Effects 0.000 claims description 6
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 claims description 4
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 claims description 4
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000011260 aqueous acid Substances 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 4
- 239000001117 sulphuric acid Substances 0.000 claims description 4
- 235000011149 sulphuric acid Nutrition 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
- 235000009962 acacetin Nutrition 0.000 claims description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- 230000002879 macerating effect Effects 0.000 claims description 2
- 239000012044 organic layer Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 229960001285 quercetin Drugs 0.000 claims description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 235000005493 rutin Nutrition 0.000 claims description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004555 rutoside Drugs 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 206010046996 Varicose vein Diseases 0.000 abstract description 7
- 208000014617 hemorrhoid Diseases 0.000 abstract description 7
- 239000002244 precipitate Substances 0.000 abstract description 7
- 210000003141 lower extremity Anatomy 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 4
- 238000005238 degreasing Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 150000002212 flavone derivatives Chemical class 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000004064 recycling Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000027185 varicose disease Diseases 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 1
- 206010002180 Anal ulcer Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 240000001579 Cirsium arvense Species 0.000 description 1
- 235000005918 Cirsium arvense Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 229960004352 diosmin Drugs 0.000 description 1
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a Herba Cirsii effective part extract, a preparation method thereof, a medicinal composition containing the Herba Cirsii effective part extract, and a use of the extract. The Herba Cirsii effective part extract includes flavonoid compounds as an only active component. The preparation method of the extract comprises the following steps: extracting Herba Cirsii, filtering, concentrating, and centrifuging to obtain a precipitate; and degreasing the precipitate through using an organic solvent to obtain the extract. The extract can be clinically used for preventing and treating hemorrhoids, lower limb varicosity and the like. The extract has the advantages of easily available raw material and easy industrialization, can be processed to prepare various dosage forms as needed, clinically provides a modern traditional Chinese medicine having the characteristics of use convenience, effective treatment and controllable quality, and brings many benefits for patients, so huge social benefits are generated.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of Chinese medicine Herba Cirsii and preparation method thereof, comprise pharmaceutical composition and the purposes of this Herba Cirsii.
Background technology
Varicosis has become the common disease of harm people's life health, weight, lack exercise, oral contraceptive, pregnancy, climacteric, obesity, aging, the factor such as heredity all can cause varicosis.Varicosis can cause the generation of hemorrhoid, and hemorrhoid are that be a kind of common disease, its sickness rate is about 25-40%, and the sickness rate of more than 50 years old old people is 60-70% due under the mucosa of rectum lower end and anal canal or the subcutaneous varicosis of anus edge, expand and cause.When patient suffers from hemorrhoid, there will be have blood in stool, the symptom such as hemorrhoid block comes off, pain, pruritus, bring very large inconvenience and misery to the life of patient.Varicose veins of the lower extremity is also varicose vein disease the most common, and prevalence is up to about 5-30%.Main clinical manifestation comprises lower limb Superficial veins and expands, extends, bends to bulk; Patient has that leg is heavy, weak, swollen, the twinge of acid, feeling of numbness, edema, scratchiness, exacerbation of symptoms after standing for a long time or walking; End-stage disease can occur that the scleroma of Superficial veins thrombosis is formed, venous ulcer (being commonly called as " always rotten lower limb ").There is affected part angiorrhexis acute hemorrhage in some patients, or chronic skin ulcer is prolonged does not heal, amputation and even threat to life.
It is cause cirsoid main cause that vein tube wall strength reduction and intravenous pressure raise, and therefore, increases the tension force of vein blood vessel, reduces intravenous pressure and just effectively can treat varicosis.
Herba Cirsii is the dry aerial parts of feverfew perverse youngster's dish Cirsium setosum (Willd.) MB..Its sweet in the mouth, hardship, cool in nature; GUIXIN, Liver Channel.There is cooling blood for hemostasis, effect of removing blood stasis to reduce swelling.Its preparation blood stops immediately sheet, blood stops immediately capsule and blood stops immediately granule all for epistaxis, and spit blood, hematuria, has blood in stool, metrostaxis, the treatment of traumatic hemorrhage etc.But have no the related application and the research report that are used for the treatment of varicose disease about Herba Cirsii.
Summary of the invention
An object of the present invention is to provide a kind of Herba Cirsii with good varicosis activity and treatment hemorrhage.
Another object of the present invention is the preparation method providing a kind of above-mentioned Herba Cirsii.
Another object of the present invention is to provide a kind of pharmaceutical composition comprising above-mentioned Herba Cirsii.
Another object of the present invention is to provide the purposes of above-mentioned Herba Cirsii.
The present invention, on the basis studied Herba Cirsii chemical composition and pharmacologically active, finds that the flavones ingredient comprised in this plant has the edema significantly suppressing local inflammation to cause, the effect reducing faint pulse vascular permeability.
The object of the invention is to be achieved through the following technical solutions:
On the one hand, the invention provides a kind of Herba Cirsii, described Herba Cirsii comprises the flavone compound as sole active agent.
Preferably, described flavone compound mainly comprises linarin, rutin, acacetin and Quercetin etc.
Preferably, in described Herba Cirsii, the content of Flavonoids is greater than 50%(weight).
On the other hand, the invention provides a kind of method preparing above-mentioned Herba Cirsii, said method comprising the steps of:
(1) Herba Cirsii medical material is got through solvent extraction;
(2) extracting solution of step (1) gained is evaporated to proper volume, puts to room temperature, centrifugal, obtain precipitation;
(3) by the precipitation in step (2) with after organic solvent extraction defat, discard organic layer, precipitation drying after namely obtain Herba Cirsii; Or the precipitation aqueous slkali in step (2) is dissolved, filters, after filtrate being purified with macroporous adsorptive resins, obtain Herba Cirsii.
Preferably, the extracting method in described step (1) is warm macerating, hot reflux and/or percolation; Preferably, the solvent in described step (1) be selected from water, aqueous slkali, methanol, ethanol and acetone one or more, wherein, when extracting with aqueous slkali, step also comprises the step first with aqueous acid, solution ph being adjusted to 3-7 in (2); Preferred described aqueous slkali is lime water, sodium hydrate aqueous solution, potassium hydroxide aqueous solution or aqueous sodium carbonate etc.; Preferably, described acid is hydrochloric acid or sulphuric acid etc.
Preferably, the organic solvent in described step (3) is petroleum ether, ether, dichloromethane, chloroform or ethyl acetate etc.; Preferably, the aqueous slkali in described step (3) is lime water, sodium hydrate aqueous solution, potassium hydroxide aqueous solution or aqueous sodium carbonate etc.; Preferably, the macroporous adsorptive resins in described step (3) is nonpolarity macroporous adsorptive resins chromatographic column, as HPD-300 macroporous adsorptive resins etc.
Preferably, described step (3) comprises the precipitation aqueous slkali after by defat further and dissolves, and filters, adds aqueous acid adjust ph to 3-7 in filtrate, and by the sedimentation and filtration of separating out, washing, namely obtains Herba Cirsii after drying; Preferably, described aqueous slkali is lime water, sodium hydrate aqueous solution, potassium hydroxide aqueous solution or aqueous sodium carbonate etc., and preferably, described acid is hydrochloric acid or sulphuric acid etc.
Above-mentioned preparation method is simple, extraction effect good, be easy to commercial introduction application.
Another aspect, the invention provides a kind of pharmaceutical composition, and described pharmaceutical composition comprises above-mentioned Herba Cirsii.
Preferably, described pharmaceutical composition is capsule, tablet, granule, drop pill, soft capsule, dispersible tablet, oral cavity disintegration tablet, slow releasing tablet, controlled release tablet, injection, transfusion or injectable sterile powder.
Conventional method can be adopted Herba Cirsii and any one or more than one pharmaceutic adjuvants, as starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, Polyethylene Glycol, magnesium stearate, micropowder silica gel, glucose, mannitol, xylitol, glycine etc. are mixed and made into above-mentioned dosage form.
Again on the one hand, the invention provides described Herba Cirsii and prepare the purposes prevented and/or treated in the medicine of varicose vein disease.
Preferably, wherein said varicose vein disease is hemorrhoid or varicose veins of the lower extremity etc.
In Herba Cirsii, the content assaying method of total flavones is as follows:
The mensuration (spectrophotography) of total flavones
The preparation of reference substance solution: the linarin reference substance that precision takes dry constant weight is appropriate, makes the solution of every 1ml containing 15 μ g with dissolve with methanol, to obtain final product.
The preparation of need testing solution: precision takes this product powder 50mg, and put in 10ml measuring bottle, adding distil water is dissolved to scale, shakes up, filters.Precipitation connects filter paper and is placed in 100ml tool plug conical flask, and add methanol 50ml, accurately weighed weight, supersound process 30min, weighs again, adds the weight that methanol supplies less loss, shakes up, and filters.Get subsequent filtrate 1ml, put in 25ml measuring bottle, add methanol to scale, shake up, to obtain final product.
The drafting of standard curve: precision measure linarin reference substance solution (0.13mg/ml) 1.0,2.0,3.0,4.0,5.0,6.0ml, putting respectively in 25ml measuring bottle, add methanol to scale, shake up, take methanol as blank, measures absorbance at 326mn wavelength place.With trap (A) for vertical coordinate, concentration C (μ gml
-1) be abscissa, drawing standard curve.
Algoscopy: get need testing solution take methanol as blank, according to spectrophotography (China's coastal port annex VA), measures trap at 326nm wavelength place.
Preliminary study is carried out to the pharmacodynamics part of medicine of the present invention, found that medicine Dichlorodiphenyl Acetate of the present invention causes rat Perianal ulceration and has obvious therapeutic action.On the basis of above-mentioned pharmacological activity test, Herba Cirsii can be used for the prevention and treatment of diseases such as hemorrhoid, varicose veins of the lower extremity clinical.
Medicine material source of the present invention is easy to get, be easy to industrialization, various dosage form can be made as required, for clinical providing uses convenient, that treatment is more effective, quality is more controlled modern Chinese medicine, for patient brings more benefit, thus create huge social benefit.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is further described in detail, the embodiment provided only in order to illustrate the present invention, instead of in order to limit the scope of the invention.
embodiment 1
Get Herba Cirsii medical material 10kg, with 100L 80%(volume) ethanol extraction three times, each 1 hour.Collect extracting solution, decompression recycling ethanol, and be concentrated into 10L, be placed to room temperature, centrifugal, precipitate through defat with petroleum ether, be drying to obtain Herba Cirsii.By the total weight of Herba Cirsii, general flavone content is 68.9%(weight).
embodiment 2
Get Herba Cirsii medical material 10kg, with 250L 70%(volume) ethanol percolate extraction, collect percolate, decompression recycling ethanol, and be concentrated into 10L, be placed to room temperature.Centrifugal, precipitate through chloroform defat, obtain Herba Cirsii.By the total weight of Herba Cirsii, general flavone content is 65.7%(weight).
embodiment 3
Get Herba Cirsii medical material 10kg, with 100L 80%(volume) ethanol extraction three times, each 2 hours, collect extracting solution, decompression recycling ethanol, and be concentrated into 10L, be placed to room temperature.Centrifugal, precipitate through methanol supersound process, sucking filtration, discards methanol solution, and precipitation is dry, obtains Herba Cirsii.By the total weight of Herba Cirsii, general flavone content is 70.1%(weight).
embodiment 4
Get Herba Cirsii medical material 10kg, with the limewater extraction 2 times of 100L pH8-9, each 1 hour, filter, collect filtrate, salt adding acid for adjusting pH to 3-4, and is concentrated into 10L, hold over night.Centrifugal, precipitate through chloroform heat treated, sucking filtration, discards chloroform solution, and precipitation is dry, obtains Herba Cirsii.By the total weight of Herba Cirsii, general flavone content is 52.1%(weight).
embodiment 5
Get Herba Cirsii medical material 10kg, with 100L 70%(volume) ethanol extraction three times, each 2 hours, collect extracting solution, decompression recycling ethanol, and be concentrated into 10L, be placed to room temperature.Centrifugal, precipitate through the process of dichloromethane merceration, sucking filtration, discard dichloromethane solution, precipitation 20L concentration 2%(weight/volume) sodium hydrate aqueous solution dissolving, filter, in filtrate, add 20L medicinal alcohol, pH to 5 is regulated with concentrated hydrochloric acid, hold over night, separates out precipitation, sucking filtration, precipitation clear water fully cleans to pH neutral, obtains Herba Cirsii.By the total weight of Herba Cirsii, general flavone content is 72.9%(weight).
embodiment 6
Get Herba Cirsii medical material 10kg, with 100L 80%(volume) ethanol extraction secondary, each 2 hours, collect extracting solution, decompression recycling ethanol, and be concentrated into 10L, be placed to room temperature.Centrifugal, precipitation 20L concentration 2%(weight/volume) sodium hydrate aqueous solution dissolving, filter, get filtrate, by HPD-300 macroporous adsorptive resins, it is neutral for being first washed till effluent pH value with distilled water, use 70%(volume again) concentration ethanol eluting 20L, collect 70%(volume) alcoholic solution, decompression recycling ethanol is also concentrated into dry, obtains Herba Cirsii.By the total weight of Herba Cirsii, general flavone content is 85.3%(weight).
embodiment 7
Get Herba Cirsii 100g, micropowder silica gel is appropriate, mix homogeneously, adopts capsules preparation technique preparation, obtains Herba Cirsii capsule.
embodiment 8
Get Herba Cirsii 100g, be added in the polyethylene glycol 6000 of 200g melting, adopt drop pill preparation technology preparation, obtain Herba Cirsii drop pill.
embodiment 9
Get Herba Cirsii 100g, dextrin 200g, mix homogeneously, granulate, sieve, dry, obtain the granule of Herba Cirsii; Maybe by obtained granule through further tabletting, dry, obtain the tablet of Herba Cirsii.
embodiment 10
Get Herba Cirsii 100g, hydroxypropyl emthylcellulose 100g, sodium carboxymethyl cellulose 60g, lactose 40g, mix homogeneously, granulate, dry, tabletting, obtains the slow releasing tablet of Herba Cirsii.
embodiment 11
Get Herba Cirsii 100g, microcrystalline Cellulose 120g, sodium carboxymethyl cellulose 30g, micropowder silica gel 1g, mix homogeneously, tabletting, obtain the dispersible tablet of Herba Cirsii.
embodiment 12
Get Herba Cirsii 100g, vegetable oil 250g, mixing, makes capsule casing material with gelatin, is pressed into soft capsule, obtain the soft capsule of Herba Cirsii.
embodiment 13
Get Herba Cirsii 10g, be dissolved in 500ml water for injection, adopt existing injectable sterile powder preparation technology to prepare, obtain Herba Cirsii injectable sterile powder dosage form.
embodiment 14
Get Herba Cirsii 10g, be dissolved in 1000ml water for injection, adopt process for preparation of injection, obtain Herba Cirsii injection (containing transfusion).
test example 1
The curative effect of medicine of the present invention is proved by following pharmacodynamics test:
1, test material
1.1 medicines and reagent
Herba Cirsii: sample prepared by embodiment 1, brown ceramic powder (general flavone content is greater than 50%(weight)).The solution being made into suitable concn with normal saline is for experiment.
Alvenor (diosmin sheet): purchased from Shi Weiya (Tianjin) pharmaceutical Co. Ltd.
1.2 animal
Rat: SD rat, male and female dual-purpose, body weight 160-180g, purchased from Hua Bukang biotech inc, Beijing.
2, Dichlorodiphenyl Acetate causes the impact of rat Perianal ulceration
Get SD rat 50, male and female half and half, body weight 160-180g.Perianal ulcer is caused: be that the filter paper of 8mm launches and put into glacial acetic acid fully to soak by equal and opposite in direction internal diameter with acetic acid, then all rats filter paper being soaked with glacial acetic acid is sticked anus, filter paper need be close to anal skin and mucosa, and 0.5min, 1min change filter paper.Within 2nd day, divide 4 groups at random by rat, gastric infusion by body weight and ulcer level.Model control group is to equal-volume distilled water; Herba Cirsii 200,400mg/kg group; Positive controls.In administration the 3rd, 5,7,9 days according to rat ulcer healing state, evaluation ulcer level.Evaluation criteria: have ulcer sepage 1 point; A little ulcer sepage 2 points; Eschar is had substantially to heal 3 points; Heal 4 points completely.White ulcer surface, crissum swelling have inflammatory seep is all there is in each treated animal after sticking the glacial acetic acid filter paper of 99%.
Table 1 Herba Cirsii Dichlorodiphenyl Acetate cause rat Perianal ulceration impact (
, n=10)
Table 1 result shows, Herba Cirsii 200 and 400mg/kg dosage treated animal self administration of medication play Perianal ulceration on the 5th day and namely take an evident turn for the better, substantially, healed by the 9th day, ulcer level scoring is compared with model control group significant difference (P<0.05 or P<0.01).
Therefore, Chinese medicine Herba Cirsii of the present invention has good therapeutic effect to Perianal ulceration, suppresses the edema that local inflammation causes significantly.
Claims (10)
1. the purposes of a Herba Cirsii in the medicine preparing the edema preventing and/or treating Perianal ulceration and/or caused by local inflammation, wherein, in described Herba Cirsii, the weight percentage of Flavonoids is greater than 50%, and described Herba Cirsii is prepared by the method comprised the following steps:
(1) Herba Cirsii medical material is got through solvent extraction;
(2) extracting solution of step (1) gained is evaporated to proper volume, puts to room temperature, centrifugal, obtain precipitation;
(3) by the precipitation in step (2) with after organic solvent extraction defat, discard organic layer, precipitation drying after namely obtain Herba Cirsii; Or the precipitation aqueous slkali in step (2) is dissolved, filters, after filtrate being purified with macroporous adsorptive resins, obtain Herba Cirsii;
Wherein, solvent in described step (1) be selected from water, aqueous slkali, methanol, ethanol and acetone one or more, wherein, when extracting with aqueous slkali, step also comprises the step first with aqueous acid, solution ph being adjusted to 3-7 in (2);
Organic solvent in described step (3) is petroleum ether, ether, dichloromethane, chloroform or ethyl acetate.
2. purposes according to claim 1, wherein, described flavone compound mainly comprises linarin, rutin, acacetin and Quercetin.
3. purposes according to claim 1, wherein, the extracting method in described step (1) is warm macerating, hot reflux and/or percolation.
4. purposes according to claim 1, wherein, described aqueous slkali is lime water, sodium hydrate aqueous solution, potassium hydroxide aqueous solution or aqueous sodium carbonate.
5. purposes according to claim 1, wherein, described acid is hydrochloric acid or sulphuric acid.
6. purposes according to claim 1, wherein, the macroporous adsorptive resins in described step (3) is nonpolarity macroporous adsorptive resins chromatographic column.
7. purposes according to claim 6, wherein, described nonpolarity macroporous adsorptive resins chromatographic column is HPD-300 macroporous adsorptive resins.
8. purposes according to any one of claim 1 to 7, wherein, described step (3) comprises the precipitation aqueous slkali after by defat further and dissolves, filter, aqueous acid adjust ph is added to 3-7 in filtrate, by the sedimentation and filtration of separating out, washing, namely obtains Herba Cirsii after drying.
9. purposes according to claim 8, wherein, described aqueous slkali is lime water, sodium hydrate aqueous solution, potassium hydroxide aqueous solution or aqueous sodium carbonate.
10. purposes according to claim 8, wherein, described acid is hydrochloric acid or sulphuric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210145120.1A CN103385902B (en) | 2012-05-11 | 2012-05-11 | Traditional Chinese medicine Herba Cirsii effective part extract, and preparation method, medicinal composition and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210145120.1A CN103385902B (en) | 2012-05-11 | 2012-05-11 | Traditional Chinese medicine Herba Cirsii effective part extract, and preparation method, medicinal composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103385902A CN103385902A (en) | 2013-11-13 |
| CN103385902B true CN103385902B (en) | 2015-07-08 |
Family
ID=49530437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210145120.1A Active CN103385902B (en) | 2012-05-11 | 2012-05-11 | Traditional Chinese medicine Herba Cirsii effective part extract, and preparation method, medicinal composition and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103385902B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104472221B (en) * | 2014-12-22 | 2017-06-16 | 四川藏宝虫草生物科技有限公司 | A kind of method by natural cordyceps fructification fermented hypha |
| CN104730068A (en) * | 2015-01-16 | 2015-06-24 | 李玉山 | Detection method for pure micronized diosmin crude drug |
| CN107441135A (en) * | 2017-08-12 | 2017-12-08 | 河南中医药大学 | Field thistle general flavone is preparing the application in treating cerebral ischemia and focal brain ischemia medicament repeatedly |
| CN111700923A (en) * | 2020-07-29 | 2020-09-25 | 江苏师范大学 | Extraction method of herba cepbalanoplosis segeti total flavonoids |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232982A (en) * | 2010-05-04 | 2011-11-09 | 天津药物研究院 | Extract product of herba cephalanoploris effective position, preparation method thereof and purpose thereof |
| CN102258592A (en) * | 2010-05-31 | 2011-11-30 | 景向虎 | Ointment of traditional Chinese medicine and western medicine for treating hemorrhoid |
-
2012
- 2012-05-11 CN CN201210145120.1A patent/CN103385902B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232982A (en) * | 2010-05-04 | 2011-11-09 | 天津药物研究院 | Extract product of herba cephalanoploris effective position, preparation method thereof and purpose thereof |
| CN102258592A (en) * | 2010-05-31 | 2011-11-30 | 景向虎 | Ointment of traditional Chinese medicine and western medicine for treating hemorrhoid |
Non-Patent Citations (2)
| Title |
|---|
| 崔磊等.芒硝与小蓟等煮水熏洗治痔疮效果分析.《中国医药导报》.2006,第3卷(第3期),79. * |
| 杨星昊等.大孔吸附树脂分离纯化小蓟总黄酮的研究.《浙江中医杂志》.2006,第41卷(第1期),50-52. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103385902A (en) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003260985B2 (en) | Extraction and purification method of active constituents from stem of Lonicera japonica Thunb., its usage for anti-inflammatory and analgesic drug | |
| CN101161251B (en) | Teasel root total saponin as well as its extracting method and application | |
| CN102349959B (en) | Preparation method of effective part of lilac daphne flower bud general flavone aglycon and application of effective part in medicament for resisting immuno-inflammation | |
| RU2565410C2 (en) | METHOD OF OBTAINING HIGHLY PURIFIED ASIATICOSIDE COMPOSITION FROM Centella asiatica AND METHOD OF APPLICATION THEREOF | |
| CN103385902B (en) | Traditional Chinese medicine Herba Cirsii effective part extract, and preparation method, medicinal composition and use thereof | |
| CN1267113C (en) | Extract of mulberry twig and its extracting process and novel usage | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN1931868A (en) | Figwort total phenyl glycoside and its prepn process and application | |
| CN105362325A (en) | Traditional Chinese medicine chrysanthemum indicum extract and preparation method, pharmaceutical composition and application thereof | |
| CN111671827B (en) | Application of callicarpa nudiflora extract in preparation of ulcerative colitis medicines | |
| CN106421075B (en) | A kind of preparation method and application of bamboo willow antioxidant activity component | |
| CN102671059A (en) | Smilax extract, and preparation method and application thereof | |
| CN102784157B (en) | The purposes of Gracillin and the pharmaceutical composition containing Gracillin | |
| CN103933100A (en) | Preparation method of total alkaloid of Chinese mahonia stem and applications of total alkaloid of Chinese mahonia stem in preparation of drugs for preventing and treating gastric ulcer | |
| CN104107225B (en) | Chinese crude drug Radix Polygalae anticoagulation effective site and extracting method thereof and application | |
| WO2009144744A2 (en) | Compositions comprising euphorbia prostrata and process of preparation thereof | |
| CN1961912B (en) | Chinese medicinal composition having pain-easing bleeding-stopping functions | |
| CN108096270B (en) | Pharmaceutical composition for treating diabetic nephropathy | |
| CN101564418B (en) | Pharmaceutical composition for treating oral ulcer | |
| CN102232982A (en) | Extract product of herba cephalanoploris effective position, preparation method thereof and purpose thereof | |
| CN107375409B (en) | Application of bauhinia championii polymethoxyl total flavonoids in treatment and prevention of gastric ulcer | |
| CN101181283B (en) | Ant-ihemorrhoid pharmaceutical combination | |
| CN101940585A (en) | Composite using orientin-2'-O-beta-L-galactoside as main component and application thereof | |
| CN105412286A (en) | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof | |
| CN106421076A (en) | Preparation method and application of bamboo-willow bark anti-inflammatory activity extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231013 Address after: 4th Floor, Building B1, No. 306 Huiren Road, Binhai Science and Technology Park, Binhai New Area, Tianjin, 300451 Patentee after: Heguang Traditional Chinese Medicine Technology (Tianjin) Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd. |
|
| TR01 | Transfer of patent right |